LivaNova logo

LivaNova

LIVN | NASDAQ
Chart Builder DCF Calculator
$92.44
+$1.12 (+1.23%)
At close: Nov 16, 2026, 4:00 PM ET
$92.44
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+1.23%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
64.6
Fundamentals Strong
Market Sentiment Bullish
Moat Narrow
Sector Rank #97/1021 (Top 10%)

Key Statistics

Market Data

Market Cap $5.09B
1D Range
90.77 94.80
52W Range
53.42 94.80

Valuation (TTM)

PE 26.41
PB 3.71
EV/EBITDA 23.07

Valuation (NTM)

Forward PE 20.61
Forward PEG 1.72
Price Target $93.00
Loading financial charts...

Profile

LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardi...

Sector Healthcare
Employees 3,300
IPO Date Oct 19, 2015
Fiscal Year January - December

Latest News

LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up

4 days ago · seekingalpha.com

LivaNova: Paying Off The Last Legacy Bill Just As The Sleep Apnea Market Opens Up
LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript

8 days ago · seekingalpha.com

LivaNova PLC (LIVN) Presents at 2026 UBS Global Healthcare Conference Transcript
LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

LivaNova PLC (LIVN) Q3 2026 Earnings Call Transcript
LivaNova Q3 Earnings Call Highlights

13 days ago · marketbeat.com

LivaNova Q3 Earnings Call Highlights
LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say

13 days ago · zacks.com

LivaNova (LIVN) Reports Q3 Earnings: What Key Metrics Have to Say
LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates

13 days ago · zacks.com

LivaNova (LIVN) Surpasses Q3 Earnings and Revenue Estimates
LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

13 days ago · businesswire.com

LivaNova Reports Third-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

25 days ago · businesswire.com

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · seekingalpha.com

LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LivaNova Director Sells 1,650 Shares for $131,500

2 months ago · fool.com

LivaNova Director Sells 1,650 Shares for $131,500

Earnings

Latest Earnings
Nov 4, 2026
EPS
$1.23
Beat +16.04%
REV
$393.1M
Beat +3.14%
Next Earnings
Feb 24, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$93.00
Upside
+0.61%
Buy (7)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.